智通财经网·2025-08-14 03:33Core Viewpoint - Tiger Med (03347) has seen its stock price increase by over 7%, reaching HKD 59.65, with a trading volume of HKD 115 million, driven by positive market sentiment and institutional buying [1] Group 1: Stock Performance - Tiger Med's stock price has risen 83% year-to-date, reflecting a strong recovery in the Chinese innovative drug market expected in the first half of 2025 [1] - The stock experienced a 7.19% increase as of the latest report, indicating robust investor interest [1] Group 2: Institutional Investment - E Fund Management Co., Ltd. has increased its holdings in Tiger Med by purchasing 549,100 shares on August 8, 66,200 shares on August 5, and 1,181,600 shares on July 29 [1] Group 3: Market Outlook - According to Citi, the biotechnology financing environment is expected to improve, which will likely enhance Tiger Med's investment returns beyond its core clinical service fees [1] - The company is anticipated to see positive year-on-year growth in sales for the second quarter, contrasting with a decline observed over the previous five quarters [1] - Operating profit margins are expected to show quarterly fluctuations, with new orders projected to improve on a quarterly basis starting from the second quarter [1]